Biolargo, Inc. income statement BLGO

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Biolargo, Inc. reported revenue of $7.8 million, down 56.3% from the year before. It recorded a net loss of $15.2 million. The operating loss came to $14.9 million, an operating margin of -191.3%. Over the twelve months ended Jun 30, 2026, revenue was $4.1 million and the net loss was $18.8 million. Across the 10 fiscal years shown, revenue grew from $281,106 in fiscal 2016 to $7.8 million in fiscal 2025, about 44.6% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	4 -71.0%	8 -56.3%	18 +45.4%	12 +107.9%	6 +132.5%	3 +4.1%	2 +30.7%	2 +36.4%	1 +164.2%	1 +83.6%	0 +120.3%
Cost of revenue	2 -68.0%	4 -56.1%	10 +63.4%	6 +100.7%	3 +112.0%	1 +18.6%	1 +27.4%	1 +27.2%	1 +130.0%	0 +205.1%	0 +70.6%
Gross profit	2 -74.5%	3 -56.6%	8 +27.6%	6 +115.4%	3 +159.0%	1 -10.2%	1 +34.1%	1 +47.5%	1 +221.8%	0 +10.1%	0 +167.5%
Research and development	3 +16.6%	3 -10.0%	3 +26.3%	2 +73.0%	1 -3.5%	1 +2.2%	1 -9.1%	1 -14.4%	2 +5.5%	2 +17.9%	1 +101.9%
Selling, general and administrative	13 +26.8%	12 +26.5%	9 +15.4%	8 +19.7%	7 +9.1%	6 -17.4%	7 +21.7%	6 +15.5%	5 +20.0%	4 +19.2%	4 +4.6%
Operating income	-18 -185.7%	-15 -243.0%	-4 +5.4%	-5 +15.0%	-5 +20.5%	-7 +10.6%	-8 -13.2%	-7 -4.4%	-6 -8.8%	-6 -19.5%	-5 -18.0%
Interest income	0	0 +426.3%	0	—	—	—	—	—	—	—	—
Interest expense	—	1	—	—	—	—	—	—	—	—	—
Equity in earnings of affiliates	-0 -560.0%	-0 -180.0%	-0 +64.3%	-0 +6.7%	-0 +0.0%	-0 +59.5%	-0	—	—	—	—
Pretax income	—	-15	—	—	—	—	—	—	—	—	—
Income tax	—	—	0	—	—	—	—	—	—	—	—
Net income	-19 -184.9%	-15 -249.4%	-4 +6.5%	-5 +9.4%	-5 +25.6%	-7 +28.9%	-10 +15.2%	-11 -7.0%	-11 -12.0%	-10 -18.2%	-8 -59.0%
Net income to common	-14 -271.6%	-12 -390.4%	-2 +31.4%	-4 +21.7%	-4 +36.8%	-7 +16.0%	-8 +21.1%	-11 -4.6%	-10 -12.1%	-9 -16.3%	-8 -55.1%
Basic EPS	-0.05 -255.0%	-0.04 -300.0%	-0.01 +0.0%	-0.01 +50.0%	-0.02	—	—	—	—	—	—
Weighted average shares, basic	316 +4.7%	307 +3.0%	298 +4.3%	286 +6.6%	268 +8.5%	247 +26.1%	196 +28.9%	152 +24.7%	122 +23.3%	99 +12.5%	88 +4.5%
Other measures
Depreciation and amortization	0 -16.8%	0 -6.5%	0 +50.5%	0	—	—	—	—	—	—	—
EBITDA	-18 -191.0%	-15 -252.3%	-4 +6.7%	-4	—	—	—	—	—	—	—
Interest coverage	—	-27.51x	—	—	—	—	—	—	—	—	—
Margins
Gross margin	39.91%	43.86%	44.17%	50.32%	48.56%	43.58%	50.49%	49.22%	45.53%	37.39%	62.34%
Operating margin	-443.95%	-191.31%	-24.36%	-37.45%	-91.60%	-267.80%	-311.80%	-359.81%	-470.09%	-1,142.16%	-1,755.52%
Pretax margin	—	-195.61%	—	—	—	—	—	—	—	—	—
Profit margin	-460.34%	-195.61%	-24.45%	-38.00%	-87.22%	-272.38%	-398.85%	-614.72%	-784.16%	-1,849.43%	-2,872.35%
EBITDA margin	-440.67%	-189.44%	-23.49%	-36.61%	—	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Chemicals & Allied Products (SIC 2800)
Listed as: BLGO (OTC)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Westminster, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 880242
Former names: NUWAY MEDICAL INC (until Apr 3, 2007); NUWAY ENERGY INC (until Feb 5, 2003); LATIN AMERICAN CASINOS INC (until Feb 15, 2001)

Other Chemicals & Allied Products companies

All 20 Chemicals & Allied Products companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.